The diagnosis of malignant mesothelioma in effusion cytology: A reappraisal and results of a multi-institution survey

Cancer Cytopathology

Volumn 121, Issue 12, 2013, Pages 703-707

  Paintal, Ajit ^a   Raparia, Kirtee ^a   Zakowski, Maureen F ^b,c   Nayar, Ritu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cytology; Effusion; Fluid; Mesothelioma; Pleura

Indexed keywords

PROTEIN P16;

ADENOCARCINOMA; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CYTODIAGNOSIS; EFFUSION CYTOLOGY; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; PATHOLOGIST; PERITONEUM MESOTHELIOMA; PLEURA EFFUSION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; ADULT; AGED; CANCER STAGING; COHORT ANALYSIS; CYTOLOGY; EFFUSION; EVALUATION STUDY; FEMALE; INFORMATION PROCESSING; LIQUID; LUNG TUMOR; MALE; MALIGNANT PLEURA EFFUSION; MESOTHELIOMA; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; PATHOLOGY; PLEURA; PLEURA TUMOR; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR INVASION; CLINICAL TRIAL; LUNG NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROCEDURES;

CYTOLOGY; EFFUSION; FLUID; MESOTHELIOMA; PLEURA;

ADULT; AGED; BIOPSY, NEEDLE; COHORT STUDIES; CYTODIAGNOSIS; DATA COLLECTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84893494400     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21342     Document Type: Article

References (14)

1. Husain AN, Colby T, Ordonez N, et al; International Mesothelioma Interest Group. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137:647-667.
2. Travis WD, Brambilla E, Müller-Hermlink HK, Harris CC, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
3. Nguyen GK. Cytopathology of pleural mesotheliomas. Am J Clin Pathol. 2000;114(suppl):S68-S81.
4. Tao LC. The cytopathology of mesothelioma. Acta Cytol. 1979;23: 209-213.
5. Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135: 619-627.
6. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008; 132:397-401.
7. Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010;38:874-879.
8. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:106-109.
9. DiBonito L, Falconieri G, Colautti I, Bonifacio Gori D, Dudine S, Giarelli L. Cytopathology of malignant mesothelioma: a study of its patterns and histological bases. Diagn Cytopathol. 1993;9:25-31.
10. Sherman ME, Mark EJ. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma. Arch Pathol Lab Med. 1990;114:845-851.
11. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19:514-523.
12. Pinheiro C, Longatto-Filho A, Soares TR, et al. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. Diagn Cytopathol. 2012;40:478-483.
13. Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol. 2013;37:421-426.
14. Neragi-Miandoab S, Richards WG, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg. 2008;6:293-297.